In preclinical studies of Wilms tumor, the bivalent BRD4 inhibitor AZD5153 led to reduced MYC levels in cell lines derived from anaplastic and non-anaplastic Wilms tumor, and inhibited tumor growth in patient-derived xenografts [194]. This evidence concerns the gene BRD4 and Wilms tumor.